|
|
|
Volumn 26, Issue 5 SUPPL. 17, 1999, Pages 24-27
|
|
Approaches to the treatment of patients with hormone-sensitive prostate cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
DOCETAXEL;
ESTRAMUSTINE;
ETOPOSIDE;
ISOTRETINOIN;
MITOXANTRONE;
PACLITAXEL;
PROSTATE SPECIFIC ANTIGEN;
PROTEIN BCL 2;
PROTEIN P53;
RIBONUCLEASE;
SOMATOMEDIN C;
TAMOXIFEN;
TRANSFORMING GROWTH FACTOR BETA;
VINBLASTINE;
ANTINEOPLASTIC ACTIVITY;
CANCER HORMONE THERAPY;
CANCER RESISTANCE;
CLINICAL TRIAL;
DRUG EFFICACY;
GENE OVEREXPRESSION;
HUMAN;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CANCER;
PROTEIN EXPRESSION;
REVIEW;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DRUG RESISTANCE, NEOPLASM;
GENE EXPRESSION REGULATION, NEOPLASTIC;
GENES, BCL-2;
HUMANS;
MALE;
NEOPLASMS, HORMONE-DEPENDENT;
PROSTATIC NEOPLASMS;
|
|
EID: 0033452117
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (19)
|
|
References (31)
|
